Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • SAB
    • Contact Us
  • Pipeline
    • Our Pipeline
  • Science
  • Sjögren’s Clinical Trial
  • Publications
  • News

Follow us on:

Linkedin page opens in new windowFacebook page opens in new window
  • About Us
    • Our Company
    • Management Team
    • SAB
    • Contact Us
  • Pipeline
    • Our Pipeline
  • Science
  • Sjögren’s Clinical Trial
  • Publications
  • News

Publications

Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Randomized Phase 2 Trial of RSLV-132

May 11, 2024
Read more

Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132

February 8, 2024
Read more

Improvement of Severe Fatigue Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

December 8, 2020

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

Read more

Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study

November 16, 2016

Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study

Read more

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus

August 17, 2016

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus

Read more
Load more
Resolve Therapeutics
Resolve Therapeutics, LLC
1951 NW 7th Ave.
Suite 300
Miami, FL 33136

[email protected]
© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top